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Abstract
Background
Antiretroviral therapy has increased longevity for people living with HIV (PLWH). As a result,
PLWH increasingly experience the common diseases of aging and the resources needed to
manage these comorbidities are increasing. This paper characterizes the number and types
of comorbidities diagnosed among PLWH covered by Medicare and examines how non-HIV
comorbidities relate to outpatient, inpatient, and pharmaceutical expenditures.
Methods
The study examined Medicare expenditures for 9767 HIV-positive Californians enrolled in
Medicare in 2010 (7208 persons dually covered by Medicare and Medicaid and 2559 with
Medicare only). Costs included both out of pocket costs and those paid by Medicare and
Medicaid. Comorbidities were determined by examining diagnosis codes.
Findings
Medicare expenditures for Californians with HIV averaged $47,036 in 2010, with drugs
accounting for about 2/3 of the total and outpatient costs 19% of the total. Inpatient costs
accounted for 18% of the total. About 64% of the sample had at least one comorbidity in
addition to HIV. Cross-validation showed that adding information on comorbidities to the
quantile regression improved the accuracy of predicted individual expenditures. Non-HIV
comorbidities relating to health habits—diabetes, hypertension, liver disease (hepatitis C),
renal insufficiency—are common among PLWH. Cancer was relatively rare, but added sig-
nificantly to cost. Comorbidities had little effect on pharmaceutical costs, which were domi-
nated by the cost of antiretroviral therapy, but had a major effect on hospital admission.
PLOS ONE | https://doi.org/10.1371/journal.pone.0189392 December 14, 2017 1 / 13
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Zingmond DS, Arfer KB, Gildner JL,
Leibowitz AA (2017) The cost of comorbidities in
treatment for HIV/AIDS in California. PLoS ONE 12
(12): e0189392. https://doi.org/10.1371/journal.
pone.0189392
Editor: Graciela Andrei, Katholieke Universiteit
Leuven Rega Institute for Medical Research,
BELGIUM
Received: June 30, 2017
Accepted: November 26, 2017
Published: December 14, 2017
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: There are legal,
contractual restrictions on sharing the data that
we used. Medicare and Medicaid insurance
claims data for HIV-positive Californians were
acquired through a confidential data use
agreement with the Center for Medicare and
Medicaid Services (CMS). As part of this
agreement, CMS and UCLA agreed that “CMS
retains all ownership rights to the data file(s)
referred to. . .in the data use agreement. . .and
that the User does not obtain any right, title, or
interest in any of the data furnished by CMS.”
Conclusions
Comorbidities are prevalent among PLWH and add substantially to treatment costs for
PLWH. Many of these comorbidities relate to health habits that could be addressed with
additional prevention in ambulatory care, thereby improving health outcomes and ultimately
reducing costs.
Introduction
Care for people infected with HIV has traditionally focused on optimal management of HIV
infection and ensuring access to providers with specialty knowledge of HIV care. The success
in managing HIV infection has led to increased survival for people living with HIV (PLWH),
with the result that in 2014 45% of Americans diagnosed with HIV were aged 50 and older.[1]
As a result, PLWH are increasingly experiencing the common diseases of aging.
Non-HIV comorbidities are common among those infected with HIV, particularly among
Medicare and Medicaid enrollees. [2–12] The prevalence of comorbidities rises with age. An
analysis of health insurance claims data found that 83% of PLWH aged 50 and older and 63%
of PLWH aged 18–49 had at least one comorbidity. In contrast, 69% of age/gender matched
controls without HIV who were 50 and older had at least one medical condition.[13] A study
of Medicare enrollees with HIV found that 20.1% had kidney disease, 19.4% had diabetes, and
27.3% had hyperlipidemia, and 16.0% experienced a cardiovascular event in 2013.[2] Cancer is
more prevalent among PLWH than in the general population.[14] Among Medicare enrollees
over 65, those with HIV were diagnosed with new cancers over a 5 year period at a rate 50%
greater than the cancer incidence rate for Medicare enrollees without HIV.[15]
Multimorbidity is also common among PLWH. Insurance claims data show that among
PLWH aged 50 and older, 22% had one medical condition in addition to HIV, 36% had 2–3
comorbidities, 15% had 4–5, and 10% had >5.[13] There is also evidence that PLWH may
develop some diseases at earlier ages than people who are not infected with HIV due to
immune exhaustion from chronic inflammation engendered by even well-controlled/treated
HIV infection.[16]. A study in Italy estimated that PLWH experience rates of non-infectious
comorbidities that were comparable to those of patients without HIV who were 10–15 years
older. [11]
As care for HIV infections has matured and PLWH are living longer without AIDS, the
resources needed to manage and treat their non-HIV comorbidities have increased in impor-
tance. One measure of these resources is the cost of treating these comorbidities, which adds to
the substantial costs of HIV/AIDS treatment. Historically, overall costs of HIV treatment have
been driven largely by the high costs of antiretrovirals and of hospitalizations.[17,18] In recent
guidelines for use of ART, HHS calls on providers to inform themselves about antiretroviral
regimen costs, patient insurance regulations, and availability of antiretroviral therapy (ART).
[19] While the costs of comorbidities have been examined for PLWH in Italy and in Canada,
little is known about how treatment for non-HIV comorbidities relate to outpatient, inpatient
and pharmaceutical costs for PLWH in the United States, particularly those who are publicly
insured.[10–12]
This paper seeks, first, to characterize the number and types of comorbidities diagnosed
among publicly-insured PLWH covered by Medicare. Secondly, we examine how comorbidi-
ties predict outpatient, inpatient and pharmaceutical expenditure.
The cost of comorbidities in treatment for HIV/AIDS
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Materials and methods
Data
Insurance claims data for HIV-positive Californians enrolled in Medicare in 2010 were
acquired through a confidential data use agreement with the Center for Medicare and Medic-
aid Services (CMS). The sample includes Medicare beneficiaries enrolled in both Medicare
(the primary payer) and Medicaid (hereafter, Duals) as well as those enrolled solely in Medi-
care (Medicare-only). We applied a case-identification algorithm to create an analysis file of
adult beneficiaries with verifiable HIV. [20] Our analyses were limited to fee-for-service Medi-
care enrollees because available data for Medicare managed care enrollees lack diagnosis fields
needed to confirm HIV status and identify comorbidities. In order to account for medication
expenditures, we required enrollment in Part D drug coverage for the entire year of 2010.
There were 7208 Californians with HIV who met the sample inclusion criteria and were dually
covered by Medicare and Medicaid and 2559 Californians who had only Medicare coverage.
Data acquisition was reviewed and approved by the CMS Privacy Board. The UCLA Institu-
tional Review Board (UCLA IRB #10–000823) reviewed the study and deemed it exempt. Data
were obtained in research identifiable files; storage, analysis, and reporting met CMS data
security requirements.
Outcome variables
This analysis separately examines health care expenditures for outpatient services, pharmaceu-
ticals, and inpatient services. Expenditures included all costs reimbursed by Medicare and
Medicaid plus costs paid by the patient (e.g. deductible and coinsurance) in each category.
Thus pharmaceutical costs include patients’ payments in the “doughnut hole” phase, where
Medicare does not reimburse for drug purchases.
Comorbidities
Diagnoses were grouped using the typology of 26 comorbidities developed by Elixhauser.
[21,22] An indicator variable for each comorbidity was set to one if an individual’s medical
claims contained an ICD-9 diagnosis code at least once in 2010 in an inpatient claim or at least
twice in outpatient claims on different days. For each individual, the number of unique comor-
bidities was calculated. AIDS-defining conditions were not included among comorbidities and
hemophilia was treated separately as a subgroup of coagulopathy due to extremely high costs.
CMS has redacted substance use diagnoses from the public use files, therefore we could not
include substance use as a comorbidity.
Individual characteristics
CMS enrollment data provided information on participant age, race, and gender. Reason for
Medicare coverage was coded as “disability” or other (e.g. aged). RUCA coding was used to
determine urban or rural designation based on participant’s zip code. An individual’s access to
an HIV specialist was indicated by whether they had an evaluation and management visit with
any provider who treated 50 or more Medicare or Medicaid HIV patients in California in
2010.
Statistical analysis
Mean and median medical costs were calculated by number of comorbidities. Multi-variable
methods were used to examine the effect of a given chronic disease on median costs, net of
other comorbidities and demographic factors. We use quantile regression to examine median
The cost of comorbidities in treatment for HIV/AIDS
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expenditures, where the goal is to minimize the absolute difference between actual and pre-
dicted costs. In order to examine the percentage increase in medical costs, we made a logarith-
mic transformation of each individual’s expenditure. Analyses were carried out using R in the
quantreg package [23]
More than 99% of the sample used outpatient care and had pharmaceutical claims in 2010.
In contrast, only a minority of patients were hospitalized in 2010 (20% of Duals and 13% of
Medicare-only). Therefore, we used logistic regression to relate each comorbidity to the proba-
bility of hospitalization, holding demographic factors and other comorbidities constant.
We fit quantile-regression models to estimate the relationship between the demographic
and comorbidity variables and the median logged outpatient and drug spending.[23] Inpatient
expenditures were modeled among patients who were hospitalized at all. Age and age squared,
standardized to have mean 0 and standard deviation 1/2, were included to allow for the qua-
dratic effect of age.[24] The resulting coefficients indicate the percentage change in the median
associated with each independent variable.
We estimated a variety of alternative models and used cross-validation to select the model
that minimized the mean absolute error (MAE) between the predicted and the observed values
for outpatient and drug costs. By assessing the models in terms of MAE, rather than root mean
square error (RMSE), we obtain a cost prediction for the typical patient. In contrast, predic-
tions from estimating models that minimize RMSE tend to overestimate costs for the majority
of patients in order to reduce prediction errors for the small percent of very high cost patients.
We compared observed costs at the individual level to costs predicted by models with no
covariates, only demographic variables and with both demographic and comorbidity mea-
sures. This provided a test of whether comorbidities have predictive value beyond that of the
demographic variables alone. For outpatient and drug costs we examined whether separate
models for Medicare-only beneficiaries and dual beneficiaries predicted costs better than a sin-
gle model that included a dummy variable distinguishing these beneficiary types. Thus, we
compared 6 models (3 sets of independent variables for both separate and combined modeling
of beneficiary type).
Inpatient costs were estimated with a two-step procedure. A logistic-regression predicted
the probability of having nonzero inpatient costs and a quantile-regression predicted the
median expenditure, conditional on having nonzero inpatient costs. The 9 models we com-
pared crossed 3 different sets of independent variables for the logistic model with the same
three sets for the quantile regression model.
We assessed each model with tenfold cross-validation by randomly assigning patients to
one of ten folds (subsamples), then predicting costs for each patient in each fold. We then cal-
culated the mean absolute error (MAE) between the predicted and observed cost for each
patient We assessed prediction accuracy based on the mean of these MAEs.
Results
Sociodemographics
The majority of this sample of PLWH who are enrolled in Medicare are male (90%) and
between the ages of 41 and 60 (72%). (Table 1). Whites comprise 57% of the sample while Afri-
can Americans account for 19% and Hispanics 20%. Over 94% of the sample live in urban
areas and approximately two-thirds (63%) had access to a provider treating 50 or more pub-
licly insured patients. Seventy four percent of the Medicare sample also have Medicaid cover-
age and most (91%) qualified for Medicare due to long-term disability.
The mean Medicare expenditure for California enrollees with HIV was $47,036 in 2010
(Table 1). Drug costs were the largest expense category, accounting for almost 2/3 of the total
The cost of comorbidities in treatment for HIV/AIDS
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($30,052). Mean outpatient costs of $8,714 amounted to 19% of total annual expenditures. The
26% of the sample who experienced an inpatient episode had mean hospital costs of $32,668.
Across the entire sample, inpatient costs accounted for 18% of total costs for the average
patient.
Comorbidities
Comorbidities were common (Table 1). About 64% of this HIV-positive sample had at least
one additional condition. Both mean and median per capita treatment costs rose monotoni-
cally with the number of comorbidities.
Table 2 shows the prevalence of individual comorbidities among sample members. The
most frequently identified comorbidity was uncomplicated hypertension (32%). A diagnosis of
complicated hypertension was received by 5% of enrollees. Uncomplicated diabetes, liver
Table 1. Prevalence, mean and median annual costs by demographics, number of comorbidities, and spending type (N = 9767).
% Mean Spending Median Spending
Enrollment Medicare Only 26.2% $41,606 $32,573
Dual 73.8% $48,964 $35,051
Sex Male 89.3% $47,010 $34,381
Female 10.7% $47,251 $34,249
Race White 56.9% $46,260 $34,791
African American 19.1% $51,062 $34,340
Hispanic 19.7% $45,208 $33,453
Other 4.3% $47,821 $34,038
Age category < = 40 9.3% $43,167 $29,330
41–50 38.2% $46,206 $33,968
51–60 33.4% $48,124 $36,417
>60 19.0% $48,697 $34,142
Eligibility Other 9.4% $47,184 $32,796
Disabled 90.6% $47,021 $34,549
Area Rural 5.1% $43,068 $32,676
Urban 94.9% $47,251 $34,467
Highest volume HIV provider 0–49 patients 37.2% $48,933 $34,202
50+ patients 62.8% $45,911 $34,485
Total spending $47,036 $34,379
Outpatient 99.8% $8,714 $4,085
Drug 99.3% $30,052 $26,633
Inpatient 26.0% $32,668 $13,487
Number of comorbidities 0 36.1% $30,312 $27,795
1 25.4% $38,260 $32,949
2 15.3% $46,108 $37,371
3 8.6% $55,492 $44,865
4 4.6% $66,330 $52,515
5 3.2% $80,047 $59,992
6 2.1% $100,861 $81,006
7 1.6% $114,451 $87,323
8–10 2.2% $135,808 $116,811
11 or more 0.9% $218,940 $203,571
Means and medians for outpatient, drug, and inpatient spending are based on non-zero spending for the respective category.
https://doi.org/10.1371/journal.pone.0189392.t001
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disease, and chronic pulmonary disease were each diagnosed in more than 10% of the sample.
The prevalence of cancer was relatively rare: 2% of the sample had lymphoma, fewer than 1%
had metastatic cancer and 6% had solid tumors without metastasis.
Mean and median per capita total expenditures for individuals with each comorbidity
group are also shown in Table 2. Costs varied substantially across diagnoses. There is a nega-
tive correlation of -0.5 between prevalence and cost (p< .05), with the least frequent comor-
bidities (like hemophilia) averaging very high per capita costs, as compared to the more
prevalent comorbidities such as hypertension.
Regression results
An individual can have more than one comorbidity, thus we examine net costs of each comor-
bidity in a multi-variable framework that controls for the presence of other comorbidities as
well as demographic factors.
Quantile regression was used to relate logged expenditures for each of the cost components
(outpatient, drugs, and inpatient costs, if hospitalized) to demographic factors and presence of
comorbidities. (Table 3). Logistic regressions modeled the probability of inpatient use.
(Table 4). Models that combined Medicare-Only and Dual samples, and included all demo-
graphic and comorbidity variables as predictors minimized MAE for outpatient and drug
Table 2. Prevalence, mean and median spending by comorbidities (N = 9767).
Comorbidities % Mean Spending Median Spending
Congestive heart failure 5.3% $104,641 $76,152
Cardiac arrhythmias 6.7% $100,330 $67,335
Valvular disease 2.7% $108,204 $72,559
Peripheral vascular disorders 4.7% $89,102 $59,363
Hypertension, uncomplicated 31.8% $62,231 $42,183
Hypertension, complicated 5.4% $108,442 $79,604
Paralysis 1.1% $112,051 $73,815
Other neurological disorders 5.3% $97,511 $64,454
Pulmonary circulation disorders 1.5% $119,181 $91,819
Chronic pulmonary disease 13.7% $74,391 $50,919
Diabetes, uncomplicated 14.4% $66,275 $45,330
Diabetes, complicated 4.4% $92,992 $62,640
Hypothyroidism 6.2% $69,416 $50,998
Renal failure 9.0% $88,320 $60,545
Liver disease 15.8% $68,169 $43,903
Peptic ulcer disease 0.7% $110,610 $66,769
Lymphoma 1.8% $73,641 $49,466
Metastatic cancer 0.6% $117,362 $91,779
Solid tumor without metastasis 6.0% $67,164 $49,879
Rheumatoid arthritis 2.3% $74,563 $48,873
Coagulopathy 3.2% $109,681 $77,177
Coagulopathy—hemophilia 0.3% $369,119 $227,917
Blood loss anemia 0.7% $128,091 $101,333
Deficiency anemia 6.9% $90,258 $60,130
Obesity 2.9% $65,049 $48,611
Weight loss 7.6% $97,346 $65,176
Fluid and electrolyte disorders 9.7% $107,681 $77,998
https://doi.org/10.1371/journal.pone.0189392.t002
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costs, although the improvement over the estimate without covariates was small. (Table 5).
The improvement in prediction was greatest for the inpatient model, where adding comorbidi-
ties reduced the MAE by 20%, from $8,489 TO $6,792. (Table 6).
Each comorbidity coefficient can be interpreted as the percentage increase in median
spending associated with this comorbidity compared to a non-disabled, white, urban, male
Table 3. Effect of comorbidities on outpatient, drug, and inpatient expenditures (percentage increase over median costs).
Outpatient Cost (n = 9767) Drug Cost (n = 9767) Conditional Inpatient Cost (n = 2538)
Coefficient Estimate
(95% CI)
Coefficient Estimate
(95% CI)
Coefficient Estimate
(95% CI)
Intercept 2,151
(1804, 2405)
21,982
(20,522,23,625)
3,697
(2321,5561)
Enrollment Dual 1.21 (1.15, 1.28) 1.04 (1.02, 1.08) 1.02 (0.80, 1.28)
Gender Female 1.19 (1.11, 1.29) 0.89 (0.86, 0.92) 0.93 (0.74, 1.09)
Age Linear 1.04 (0.98, 1.10) 1.04 (1.01, 1.07) 0.87 (0.71, 1.00)
Quadratic 1.04 (0.97, 1.09) 0.85 (0.83, 0.89) 1.07 (0.91, 1.20)
Race African American 0.84 (0.79, 0.89) 0.88 (0.85, 0.91) 1.04 (0.91, 1.28)
Hispanic 0.84 (0.79, 0.88) 0.95 (0.92, 0.99) 0.98 (0.83, 1.27)
Other 0.85 (0.75, 0.94) 0.99 (0.93, 1.04) 1.05 (0.69, 1.51)
Area Urban 1.00 (0.93, 1.15) 1.05 (0.99, 1.10) 0.98 (0.74, 1.25)
Highest vol. HIV provider 50+ patients 1.11 (1.05, 1.16) 1.08 (1.05, 1.10) 0.90 (0.78, 1.07)
Eligibility Disabled 1.05 (0.93, 1.17) 1.04 (0.98, 1.10) 1.17 (0.78, 1.67)
Comorbidities Congestive heart failure 1.26 (1.13, 1.37) 0.95 (0.88, 1.02) 1.23 (1.00, 1.52)
Cardiac arrhythmias 1.37 (1.22, 1.50) 1.01 (0.96, 1.07) 1.45 (1.26, 1.74)
Valvular disease 1.27 (1.10, 1.44) 1.02 (0.94, 1.12) 1.08 (0.85, 1.41)
Peripheral vascular disorder 1.33 (1.21, 1.52) 1.05 (0.98, 1.12) 1.19 (0.92, 1.51)
Hypertension, uncomplicated 1.22 (1.17, 1.28) 1.06 (1.03, 1.09) 1.35 (1.14, 1.64)
Hypertension, complicated 1.41 (1.26, 1.61) 0.91 (0.85, 0.98) 1.14 (0.94, 1.50)
Paralysis 1.64 (1.31, 2.02) 1.01 (0.83, 1.18) 2.02 (1.45, 2.74)
Other neurological disorders 1.40 (1.24, 1.53) 1.04 (0.98, 1.11) 1.66 (1.44, 2.09)
Pulmonary circulat. disord. 1.01 (0.85, 1.37) 1.16 (1.07, 1.35) 1.25 (0.96, 1.75)
Chronic pulmonary disease 1.36 (1.30, 1.46) 1.07 (1.03, 1.10) 1.37 (1.20, 1.65)
Diabetes, uncomplicated 1.14 (1.07, 1.23) 1.10 (1.07, 1.15) 1.14 (0.89, 1.33)
Diabetes, complicated 1.26 (1.12, 1.47) 0.94 (0.86, 1.03) 1.04 (0.85, 1.40)
Hypothyroidism 1.33 (1.22, 1.44) 1.12 (1.07, 1.19) 1.08 (0.84, 1.33)
Renal failure 1.40 (1.29, 1.51) 1.07 (1.02, 1.11) 1.25 (0.94, 1.50)
Liver disease 1.41 (1.32, 1.50) 1.04 (1.00, 1.07) 1.40 (1.16, 1.64)
Peptic ulcer disease 1.32 (1.00, 1.79) 0.88 (0.61, 1.06) 1.58 (1.15, 2.22)
Lymphoma 1.68 (1.43, 1.88) 0.99 (0.91, 1.07) 1.53 (1.16, 2.05)
Metastatic cancer 2.25 (1.41, 2.86) 1.05 (0.90, 1.18) 1.66 (1.07, 2.95)
Solid tumor without metastasis 1.76 (1.56, 1.92) 1.05 (1.00, 1.11) 1.20 (0.91, 1.52)
Rheumatoid arthritis 1.27 (1.11, 1.49) 1.00 (0.88, 1.11) 0.81 (0.58, 1.21)
Coagulopathy 1.13 (1.01, 1.35) 0.97 (0.88, 1.04) 1.50 (1.19, 1.84)
Hemophilia 20.39 (3.07, 40.03) 1.25 (1.00, 1.68) 2.28 (1.00, 4.29)
Blood loss anemia 1.13 (0.93, 1.35) 0.99 (0.77, 1.26) 0.90 (0.73, 1.81)
Deficiency anemia 1.66 (1.53, 1.81) 1.08 (1.01, 1.12) 1.24 (1.00, 1.44)
Obesity 1.12 (1.03, 1.26) 0.98 (0.92, 1.07) 1.56 (1.11, 2.01)
Weight loss 1.37 (1.25, 1.50) 1.05 (1.00, 1.12) 1.72 (1.40, 1.95)
Fluid and electrolyte disord. 1.17 (1.07, 1.27) 0.94 (0.89, 1.00) 2.31 (2.01, 2.67)
https://doi.org/10.1371/journal.pone.0189392.t003
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Table 4. Odds ratios and 95% confidence intervals from logistic regression of probability of hospitali-
zation on demographics and comorbidities.
Odds Ratio (95% CI)
Enrollment Dual 1.49 (1.29, 1.73)
Gender Female 1.10 (0.91, 1.32)
Age Linear 0.59 (0.51, 0.69)
Quadratic 1.03 (0.90, 1.19)
Race African American 1.00 (0.86, 1.17)
Hispanic 0.96 (0.83, 1.12)
Other 0.83 (0.61, 1.11)
Area Urban 1.48 (1.12, 1.97)
Highest volume HIV provider 50+ patients 0.92 (0.82, 1.04)
Eligibility Disabled 0.81 (0.60, 1.10)
Comorbidities Congestive heart failure 1.50 (1.13, 1.99)
Cardiac arrhythmias 3.85 (3.04, 4.87)
Valvular disease 1.88 (1.28, 2.75)
Peripheral vascular disorder 1.32 (1.00, 1.72)
Hypertension, uncomplicated 1.87 (1.65, 2.13)
Hypertension, complicated 2.81 (2.08, 3.80)
Paralysis 4.79 (2.85, 8.20)
Other neurological disorders 3.86 (3.02, 4.92)
Pulmonary circulation disorders 2.24 (1.36, 3.71)
Chronic pulmonary disease 2.65 (2.27, 3.09)
Diabetes, uncomplicated 1.02 (0.85, 1.22)
Diabetes, complicated 1.09 (0.79, 1.49)
Hypothyroidism 1.21 (0.96, 1.52)
Renal failure 0.93 (0.74, 1.18)
Liver disease 1.76 (1.52, 2.04)
Peptic ulcer disease 2.13 (1.01, 4.49)
Lymphoma 2.63 (1.79, 3.86)
Metastatic cancer 1.77 (0.82, 3.86)
Solid tumor without metastasis 2.01 (1.60, 2.51)
Rheumatoid arthritis 1.29 (0.89, 1.86)
Coagulopathy 4.73 (3.36, 6.70)
Hemophilia 0.84 (0.29, 2.22)
Blood loss anemia 3.66 (1.74, 7.95)
Deficiency anemia 1.19 (0.94, 1.50)
Obesity 1.81 (1.33, 2.46)
Weight loss 2.10 (1.70, 2.58)
Fluid and electrolyte disorders 9.89 (7.99, 12.30)
https://doi.org/10.1371/journal.pone.0189392.t004
Table 5. Effect of covariates on Mean Absolute Errors (MAE) of predictions of outpatient expenditures and drugs.
No Controls Demographic Controls Comorbidity Controls
Outpatient $6,555 $6,487 $6165
Drugs $12,932 $12,683 $12,595
https://doi.org/10.1371/journal.pone.0189392.t005
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Medicare-only enrollee of mean age with no other chronic conditions, who did not visit a high
volume provider (50+ HIV patients).
Every comorbidity examined increased the cost of outpatient treatment. While obesity and
uncomplicated diabetes had modest effects on outpatient costs, (12% and 14% increase in
median costs, respectively), all three cancers added substantially to outpatient costs. In con-
trast, pharmaceutical expenses were relatively insensitive to individual conditions, except in
the case of hemophilia.
The median inpatient cost differential associated with each comorbidity varied over a wide
range. Logistic regressions (Table 4) show that, as expected, comorbidities and the likelihood
of hospitalization are positively related. However, after controlling for comorbidities, age and
Dual status had the greatest effects on the odds of hospitalization.
Median outpatient costs also varied by patients’ demographic characteristics. Hispanic
PLWH incurred lower median cost for outpatient services, while African-Americans had
lower costs for both outpatient services and drugs. Female PLWH had about 19% higher out-
patient costs, but their medication costs were only 89% of males’. Age did not have a large
effect, net of other demographics and comorbidities. Dual enrollees, with both Medicare and
Medicaid coverage, had median outpatient costs that were 21% greater than Medicare-Only
patients. Patients with high volume providers had slightly higher outpatient and drug costs
(8% and 11%, respectively) than patients with lower volume providers.
Discussion
The findings of this paper describe how medical complexity dramatically increases the already
high baseline costs of care for PLWH. In our sample of Medicare enrollees with HIV, nearly 2/
3 (64%) had at least one non-HIV related condition, and 39% had two or more. Mean costs of
care increased from $30,312 for those without an identified comorbidity to over $46,000 for
those with 2 comorbidities, and up to $219,000 for people with 11 or more. Our data confirm
that the greater prevalence of comorbidities with increasing age of HIV-infected patients pri-
marily accounts for increased inpatient and outpatient costs with age.[10]
The prevalence of comorbidities likely will increase with the aging of the PLWH popula-
tion. For example, a modeling study in the Netherlands projects that the percentage of HIV-
positive Dutch patients who are over 50 will increase from 28% in 2010 to 73% in 2030. The
authors predict that 84% of Dutch HIV-infected patients in 2030 will have 3 or more non-
communicable diseases—mostly cardiovascular.[25] Thus there is a need to better understand
the impact of increasing comorbidities and in turn, increasing medical expenditures for treat-
ment of PLWH. The current results, which show that including information on comorbidities
improves the accuracy of predictions of median costs of treating PLWH, will allow for more
accurate forecasts of future medical costs for an aging HIV population subject to greater num-
bers of comorbidities.
In the current analyses, pharmaceutical costs account for the greatest share of costs for
PLWH, but are largely insensitive to comorbidities because the high cost of ART overshadows
Table 6. Effect of covariates on Mean Absolute Errors (MAE) of predictions of inpatient expenditures.
Independent Variables Included in Inpatient Probability Regression Independent Variables Included in Conditional Inpatient Regression
No Controls Demographic Controls Comorbidity Controls
No Controls $8,489 $8489 $9832
Demographics $8487 $8,505 $8,501
Comorbidities $7,809 $7,777 $6,792
https://doi.org/10.1371/journal.pone.0189392.t006
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the cost of drug treatment of other comorbidities. Our data show that drugs account for a 64%
of total average costs versus 18% for inpatient costs, continuing the pattern initiated when
HAART first came into wide use.[18] In 1996, drugs accounted for 34% of total costs and inpa-
tient 49% of total costs. By 1997, after wider adoption of HAART treatment, drugs’ share rose
to over half of expenditures and the share of inpatient costs fell to 33% of a total cost of $1,521
per patient per month. [18,26] HAART improved overall survival of PLWH, resulting in
extended lifetime, and greater prevalence of comorbidities in this population.
Evidence suggests that patients with HIV have greater numbers of health conditions than
age-matched controls. [11,13] Consistent with this, among private insurance beneficiaries with
pharmacy benefits, 53.6% of HIV-positive patients over 50 were prescribed more than 5 non-
ARV medications over a 12 month period versus 34.3% of HIV negative patients of the same
age group. [13]
In contrast to their moderate effect on pharmaceutical costs, comorbidities are associated
with increases in median hospital and ambulatory care costs in the PLWH population. Histori-
cally, the development of ART dramatically lowered inpatient costs by reducing hospitalization
rates for PLWH. Hospitalized PLWH are now more likely to die of conditions other than
AIDS (e.g., non-AIDS infections, cardiovascular and liver disease) than of HIV-related condi-
tions, having increased from 43% of hospital deaths among PLWH in 1995 to 70.5% of such
deaths in 2011.[27] Our findings suggest that the impact of increasing comorbidities on costs
is primarily through greater use of inpatient care, which often requires specialty procedures
and intensive care.
This analysis is unique in looking at a range of non-HIV diagnoses to isolate the effect of
each diagnosis on the resources used to treat PLWH. Our analysis examines a broad range of
comorbidities, not just one, as in Yanik. [15] The most costly comorbidities occur less fre-
quently and different comorbidities are diversely associated with each component of cost.
Some, such as hemophilia and metastatic cancer, are associated with extremely high outpatient
costs. Others, such as uncomplicated diabetes and pulmonary circulation disorders are associ-
ated with high costs for pharmaceuticals. Given the large share of spending on drugs, there is
little opportunity to trim spending on either outpatient or inpatient services. [12, 28] An alter-
native strategy would be to reduce drug expenditures by negotiating with manufacturers to
lower their prices—especially given the new recommendations to begin therapy immediately
upon diagnosis.
Evidence of the relative contribution of lifestyle factors to morbidity among PLWH is
beginning to accumulate.[29] Some have opined that lifestyle changes may have an even more
important impact on health in HIV-infected individuals than in the general population, in
part because they decrease the inflammatory state. [30] Indeed, we found that comorbidities
relating to health habits–diabetes, hypertension, liver disease (hepatitis C), renal insufficiency,
are prevalent among those infected with HIV.[2–9, 11] Thus, health related behavior change
may be even more important for PLWH than for the general population. Yet, the ability of
physicians to provide comprehensive preventive care and to monitor chronic conditions is
constrained by relatively low Medicare and Medicaid reimbursement levels for outpatient pri-
mary care, particularly as compared with Ryan White reimbursements. Reimbursements for
physician and outpatient clinics remain modest in US public insurance, and have been charac-
terized as “quite meager and . . .inadequate to cover the cost of care provision at most HIV
clinics in the United States, the majority of which are subsidized by federal and state dol-
lars.”[31] Our finding that the share and level of outpatient expenditures are low for Medicare
enrollees is particularly relevant because many former Ryan White clients, previously covered
by a comprehensive fee, are now covered through the Medicaid expansion, at relatively low
reimbursement rates.[32] Similar to Chen, [31] we conclude that outpatient reimbursements
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are low, given the high rates of preventable comorbidities and the presence of HIV treatment
guidelines that call for a minimum of two visits and two viral load assays a year, as well as a
number of immunizations and preventive health screens.
Limitations
This paper has a number of limitations. First, the data relate only to California and may not
generalize to other states. Secondly, only 20% of all PLWH have Medicare coverage. [33]
Finally, the analyses rely on insurance claims data, so we do not observe services that were not
submitted for reimbursement. However, providers had strong incentives to bill for services
they provided. Thus we have confidence in the comprehensiveness of the reports.
Conclusions
The aging of the population with HIV will increase the widespread prevalence of comorbidities
among PLWH, adding to the already high costs of treatment for this population. We have
shown that including comorbidity measures in predictions of future medical expenditures for
PLWH will improve the accuracy of the spending forecasts. Many of the comorbidities that
PLWH live with relate to potentially modifiable health habits. However, it may be difficult for
providers to effectively provide interventions to modify negative health behaviors because of
the small share of HIV care resources devoted to outpatient services.
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